Official Title
Study of the Sars-Cov2 Neuroinvasiveness - COVID19
Brief Summary

Sars-Cov2 (COVID-19) may invade the CNS inducing neurological diseases such as anosmia, ageusia, encephalitis, ischemic or hemorrhagic stroke. Management of severe neurological complications in COVID-19 patients may require ventricular cerebrospinal fluid drainage and cranial decompression. During surgery, cerebrospinal fluid, meninges and brain parenchyma can be safely removed from the patient. In this study, COVID-19 patients will be evaluated first, for the presence of Sars-Cov2 in the cerebrospinal fluid and/or biopsies and second, for the consequences of Sars-Cov2 neuroinfection in terms of inflammatory and immune responses.

Terminated
COVID19

Drug: Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies

Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies

Eligibility Criteria

Inclusion Criteria:

- COVID-19 patients requiring an external ventricular drain, a decompressive craniectomy
or an intracranial hematoma surgery

Exclusion Criteria:

- Pregnant or lactating women

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

Fondation A de Rothschild
Paris, France

Pierre BOURDILLON, MD, Principal Investigator
Fondation A. de Rothschild

Fondation Ophtalmologique Adolphe de Rothschild
NCT Number
Keywords
Sars-Cov2 neuroinvasiveness
COVID-19 RT-PCR test
MeSH Terms
COVID-19